Last reviewed · How we verify

LRA Loco-regional anesthesia

University Hospital, Angers · Phase 3 active Small molecule

LRA delivers local anesthetic agents directly to a specific anatomical region to block nerve conduction and provide regional anesthesia for surgical or procedural pain control.

LRA delivers local anesthetic agents directly to a specific anatomical region to block nerve conduction and provide regional anesthesia for surgical or procedural pain control. Used for Regional anesthesia for surgical procedures, Perioperative pain management.

At a glance

Generic nameLRA Loco-regional anesthesia
Also known as40ml Ropivacaine 0.2%
SponsorUniversity Hospital, Angers
Drug classLocal anesthetic
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Loco-regional anesthesia (LRA) involves the injection of local anesthetic drugs (such as lidocaine, bupivacaine, or ropivacaine) into or around nerves or tissue planes in a localized area, rather than systemic administration. This approach blocks sodium channels in nerve membranes, preventing action potential propagation and thereby eliminating sensation in the targeted region while preserving consciousness and minimizing systemic side effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: